Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-07-04
2006-07-04
Hui, San-Ming (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S221000, C514S389000, C514S412000, C514S423000, C514S428000
Reexamination Certificate
active
07071183
ABSTRACT:
It has been found that inhibitors of the renin-angiotensin system are useful for the treatment or prevention of conditions associated with hypoxia or impaired metabolic function or efficiency. In particular, they may be used in connection with therapy of stroke or its recurrence, the acute treatment of myocardial infarction, and the treatment or prevention of wasting or cachexia, and are thus useful in treatment of the symptoms and signs of aging. These inhibitors may also be used to enhance function in healthy subjects.
REFERENCES:
patent: 5049553 (1991-09-01), Sudilovsky
patent: 0488059 (1992-06-01), None
patent: 2 241 890 (1991-03-01), None
patent: 2 241 890 (1991-07-01), None
patent: WO 97/13513 (1997-04-01), None
patent: WO 97/21436 (1997-06-01), None
Mansoor et al., Proc. Natl. Acad. Sci., 1996;93:2714-2718.
Abstract of Langstein and Norton, Hematol Oncol Clin North Am, 1991;5(1):103-123.
Brix et al. “Bartter's syndrome. A condition with chronic hypokalemia”,Ugeskr Laeger, vol. 158, No. 38, pp. 5277-5280, Sep. 16, 1996, abstract only.
Bussmann, W.D., S. Georke, W. Schneider, M. Kaltrenbach (1988) “Angiotensin-Converting-Enzym-Hemmer bei Angina pectoris”Dtsch. med. Wschr. 113:548-550.
Cameron, N.E., M.A. cotter [1993] “Potential Therapeutic Approaches to the Treatment or Prevention of Diabetic Neuropathy: Evidence from Experimental Studies”Diabetic Medicine10(7):593-605.
Costelli et al., “Tumor necrosis factor-alpha mediates changes in tissue protein turnover in a rat cancer cachexia model,”J. Clin. Invest., vol. 92, No. 6, pp. 2783-2789, Dec. 1993.
Donatelli, M., C. Terrizzi, M. L. Bucalo, V. Russo [1991] “Comparison of the Renal Effects of Enalapril and Nifedipine in Obese Patients with Hypertension and Non-Insulin-Dependent Diabetes Mellitus”Current Therapeutic Research50(2):312-316.
Fukuzawa et al. [1997]Immunopharmacology36:49-55.
Hall, J.E. [1986] “Regulation of glomerular filtration rate and sodium excretion by angiotensin II”Federation Proceedings45(5):1431-1437.
Hayashi et al. [1989]J. Med. Chem, 32:289-297.
Kim, Noel N., et al. [1995] “Trophic effects of angiotensin II on neonatal rat cardiac myocytes are mediated by cardiac fibroblasts”American Journal of Physiology Endocrinology and Metabolism269(2):E426-E437.
Levine et al. [1990]The New England Journal of Medicine323(4):236-41.
Maltoni et al., “Serum levels of tumour necrosis factor alpha and other cytokines do not correlate with weight loss and anorexia in cancer patients,”Support Care Cancer, vol. 5, No. 2, pp. 130-135, Mar. 1997.
Mazzocchi, Giuseppina, Piera Rebuffat, Claudia Robba, Ludwig K. Malendowicz, Gastone G. Nussdorfer [1985] “Trophic effects of potassium loading on the rat zona glomerulosa: permissive role of ACTH and angiotension II”Acta Endocrinologica108(1):98-103.
Mimran, Albert, Bernard Jover, Daniel Casellas [1984] “Renal Adaptation to Sodium Deprivation”The American Journal of Medicine76(5B):14-21.
Munzenmaier, Diane H., Andrew S. Greene [1995] “Angiotensin II mediates a sustained rise in nuclear and cytoplasmic calcium via multiple receptor subtypes”American Journal of Physiology—Heart and Circulatory Physiology269(2):H565-H570.
Oliff, Allen (Merck Sharp&Dohme Research Laboratories, West Point, Pennsylvania) “The Role of Tumor Necrosis Factor(Cachectin)in Cachexia” Cell, vol. 54, pp. 141-142, Jul. 15, 1988.
Texter, Michele, Robert S. Lees, Bertram Pitt, Robert E. Dinsmore, Andrew C.G. Uprichard [1993] “The QUinapril Ischemic Event Trial (QUIET) Design and Methods: Evaluation of Chronic ACE Inhibitor Therapy After Coronary Artery Intervention” pp. 273-282.
Tracey, Kevin J., Stephen F. Lowry, Anthony Cerami, “Cachectin: A Hormone that Triggers Acute Shock and Chronic Cachexia”The Journal of Infectious Diseases, vol. 157, No. 3, pp. 413-420, Mar. 1988.
Tracey et al. “Cachectin/Tumor Necrosis Factor Induces Cachexia, Anemia, and Inflammation”J. Exp. Med., vol. 167, pp. 1211-1227, Mar. 1988.
Winkelmann, B.R. et al.European Heart Journal, XX, The European Society of Cardiology12:355 (abstract).
Erusalimsky Jorge Daniel
Martin John Francis
Montgomery Hugh Edward
Ark Therapeutics Limited
Hui San-Ming
Saliwanchik Lloyd & Saliwanchik
LandOfFree
Use of inhibitors of the renin-angiotensin system does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of inhibitors of the renin-angiotensin system, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of inhibitors of the renin-angiotensin system will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3596522